Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC
Status:
Terminated
Trial end date:
2018-07-18
Target enrollment:
Participant gender:
Summary
The overall purpose of this research study is to find a better way to treat melanoma.
The goals of this study are:
1. To measure the side effects of and find out how well patients tolerate the recMAGE-A3 +
AS15 ASCI (MAGE-A3 ASCI) treatment with or without the Poly IC:LC
2. To see how well the patient's immune system responds to the MAGE-A3 ASCI treatment with
or without the Poly IC:LC
3. To measure the rate of return of the patient's tumor after the MAGE-A3 ASCI treatment
with or without the Poly IC:LC
4. To measure the rate of return of the patient's tumor in two groups of patients: one
group positive for the gene signature, and the other group not positive for the gene
signature in their tumor after the MAGE-A3 ASCI treatment with or without the Poly
IC:LC.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute